Several other equities research analysts also recently commented on MZOR. B. Riley restated a neutral rating and issued a $25.00 price target on shares of Mazor Robotics in a research report on Friday, February 17th. Zacks Investment Research upgraded shares of Mazor Robotics from a hold rating to a buy rating and set a $26.00 price objective on the stock in a research note on Saturday, February 18th. Standpoint Research lowered shares of Mazor Robotics from a buy rating to a reduce rating and dropped their price objective for the company from $32.98 to $28.00 in a research note on Wednesday, April 19th. They noted that the move was a valuation call. Barclays PLC lowered shares of Mazor Robotics from an overweight rating to an equal weight rating and upped their price objective for the company from $31.00 to $32.00 in a research note on Monday, April 24th. They noted that the move was a valuation call. Finally, First Analysis lowered shares of Mazor Robotics from an overweight rating to an equal weight rating and upped their price objective for the company from $28.00 to $38.00 in a research note on Thursday, May 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $33.50.
Mazor Robotics (NASDAQ MZOR) traded up 0.78% during mid-day trading on Wednesday, reaching $33.75. 296,229 shares of the company’s stock traded hands. Mazor Robotics has a 52-week low of $16.18 and a 52-week high of $45.64. The company has a 50-day moving average of $38.39 and a 200-day moving average of $28.13. The company’s market capitalization is $805.78 million.
Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. The firm had revenue of $11.70 million during the quarter, compared to analysts’ expectations of $11.49 million. Mazor Robotics had a negative net margin of 45.08% and a negative return on equity of 30.90%. The firm’s revenue was up 82.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.10) EPS. Equities research analysts expect that Mazor Robotics will post ($0.75) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Mazor Robotics Ltd. (MZOR) Rating Reiterated by Needham & Company LLC” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.themarketsdaily.com/2017/06/16/mazor-robotics-ltd-mzor-given-hold-rating-at-needham-company-llc-updated-updated.html.
Several hedge funds and other institutional investors have recently made changes to their positions in MZOR. Morgan Stanley raised its position in shares of Mazor Robotics by 35.1% in the first quarter. Morgan Stanley now owns 8,520 shares of the medical instruments supplier’s stock valued at $254,000 after buying an additional 2,215 shares during the period. UBS Group AG raised its position in shares of Mazor Robotics by 2.4% in the first quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock valued at $2,976,000 after buying an additional 2,379 shares during the period. Advisors Preferred LLC acquired a new position in shares of Mazor Robotics during the third quarter valued at approximately $128,000. Cookson Peirce & Co. Inc. raised its position in shares of Mazor Robotics by 46.5% in the third quarter. Cookson Peirce & Co. Inc. now owns 15,680 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 4,980 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Mazor Robotics by 398.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after buying an additional 5,579 shares during the period. Institutional investors own 26.93% of the company’s stock.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.